• / Free eNewsletters & Magazine
  • / My Account
Home>Teva Announces Reintroduction of Generic Depo-Provera® in the United States

Teva Announces Reintroduction of Generic Depo-Provera® in the United States

Teva Announces Reintroduction of Generic Depo-Provera® in the United States

09/26/2017

Teva Announces Reintroduction of Generic Depo-Provera ® in the United States

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy.

“This reintroduction brings an additional product to a market that was previously lacking in options,” said Dr. Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”

Teva has been committed to strengthening its generic injectable business globally, by making continued investment in newer, higher-value generic injectable products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Medroxyprogesterone acetate injectable suspension, USP 150 mg/mL had annual sales of approximately $211 million in the United States, according to IMS data as of July 2017.

About Medroxyprogesterone Acetate Injectable Suspension, USP

Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term.

©2017 Morningstar Advisor. All right reserved.